Mineralys Therapeutics, Inc.
MLYS evidence brief
What we can confirm
- BioSniper Score:
- 4.6 / 10
- Market Cap:
- $2.74B
- Next Catalyst:
- PDUFA · Dec 22, 2026
What it means
What to watch
Prepared research question
What matters most for MLYS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MLYS
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, a novel aldosterone synthase inhibitor for hypertension and related conditions, with a PDUFA target date of December 22, 2026.
Key risk: Single product dependency
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials · 1 catalyst for Mineralys Therapeutics, Inc..
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, a novel aldosterone synthase inhibitor for hypertension and related conditions, with a PDUFA target date of December 22, 2026.
- Mineralys is focused on lorundrostat, an aldosterone synthase inhibitor for hypertension, with an NDA submitted to the FDA in December 2025 [sec_mda · as of 2026-08-11].
- As of June 30, 2026, the company reported cash, cash equivalents, and investments of $661.4 million [sec_mda · as of 2026-08-11].
- The company reported a net loss of $241.1 million for the period ending June 30, 2026 [sec].
- Shareholders' equity stood at $550.9 million as of June 30, 2026 [sec].
- The FDA has set a PDUFA target date of December 22, 2026 for lorundrostat [news · published 2026-08-11].
What works
- Mineralys has a strong cash position of $661.4 million as of June 30, 2026, which management believes will fund operations, including the commercial launch of lorundrostat, for at least twelve months [sec_mda · as of 2026-08-11].
- The company has strengthened its balance sheet and enhanced the long-term economics of lorundrostat through strategic financing initiatives and the repurchase of the Tanabe royalty obligation [news · published 2026-08-11].
- Mineralys has appointed an accomplished cardiovascular medicine executive as Chief Medical Officer to lead medical and late-stage clinical activities [news · published 2026-08-11].
- The company has an ongoing open-label extension trial (Transform-HTN) and is preparing for potential approval and post-marketing commitments [sec_mda · as of 2026-08-11].
What to weigh
- Mineralys has accumulated a deficit of $496.5 million as of March 31, 2026 [sec_mda · as of 2026-05-06] and reported a net loss of $241.1 million for the period ending June 30, 2026 [sec].
- The company has no approved products and its future depends entirely on the regulatory approval and commercial success of lorundrostat [sec_mda · as of 2026-08-11].
- Expenses are expected to increase substantially as the company prepares for a potential launch, including building out a pre-commercial organization and conducting ongoing regulatory activities [sec_mda · as of 2026-08-11].
- The company's financial projections are based on assumptions that may prove wrong, and actual results could vary materially [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash, cash equivalents, and investments of $661.4 million.”
SEC MD&A · August 11, 2026
PDUFA target date for lorundrostat
“PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval”
News · August 11, 2026
Accumulated deficit as of March 31, 2026
“As of March 31, 2026, we had cash, cash equivalents, and investments of $646.1 million and an accumulated deficit of $496.5 million.”
SEC MD&A · May 6, 2026
Catalyst timeline
- 2026-12-22 · PDUFA: lorundrostat — FDA decision on the lorundrostat NDA for hypertension; approval would enable commercial launch.
Risks & what to watch (4)›
Key risks
- Single product dependency — Company has no approved products; all value depends on lorundrostat's regulatory approval and commercial success [sec_mda · as of 2026-08-11].
- Regulatory uncertainty — PDUFA date is December 22, 2026; FDA may not approve, or may require additional studies [news · published 2026-08-11].
- Increasing expenses pre-launch — Expenses expected to rise substantially for commercial-readiness activities, regulatory activities, and post-marketing commitments [sec_mda · as of 2026-08-11].
- Accumulated deficit and net losses — Accumulated deficit of $496.5M as of March 31, 2026 and net loss of $241.1M for period ending June 30, 2026 [sec_mda · as of 2026-05-06][sec].
What to watch
- FDA decision on lorundrostat NDA by PDUFA date December 22, 2026 [news · published 2026-08-11].
- Commercial launch execution and pre-commercial organization build-out [sec_mda · as of 2026-08-11].
- Progress of the Transform-HTN open-label extension trial and any required post-approval studies [sec_mda · as of 2026-08-11].
- Financial burn rate and cash runway, given increasing expenses and no current product revenue [sec_mda · as of 2026-08-11].
Sources: Catalysts · News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Mineralys Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mineralys Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.21 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~69d
0 buys · 21 sells (180d)
Catalysts
Regulatory
Financials
Short Interest
as of May 7, 2026- % of float
- 12.9%
- Days to cover
- 6.2
- Shares short
- 8,778,401
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MLYS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, a novel aldosterone synthase inhibitor for hypertension and related conditions, with a PDUFA target date of December 22, 2026.
What is Mineralys Therapeutics, Inc.'s next catalyst?
Mineralys Therapeutics, Inc.'s next tracked catalyst is a PDUFA event — "PDUFA: lorundrostat" — expected December 22, 2026.
Who is the CEO of Mineralys Therapeutics, Inc.?
Dr. Jon Congleton is the chief executive officer of Mineralys Therapeutics, Inc. (MLYS).
Where is Mineralys Therapeutics, Inc. headquartered?
Mineralys Therapeutics, Inc. (MLYS) is headquartered in Radnor, PA, United States.
What therapeutic areas does Mineralys Therapeutics, Inc. focus on?
Mineralys Therapeutics, Inc. develops therapies across Cardiovascular, Respiratory, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.